PT - JOURNAL ARTICLE AU - Konno, Hiroyuki AU - Murotani, Rikuto AU - Kamada, Yukikazu TI - An Exploratory Study to Detect the Effects of the Combined Intake of Gamma-aminobutyric Acid (GABA) and L-theanine on Sleep by Wearable Device AID - 10.1101/2023.10.01.23296182 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.01.23296182 4099 - http://medrxiv.org/content/early/2023/10/03/2023.10.01.23296182.short 4100 - http://medrxiv.org/content/early/2023/10/03/2023.10.01.23296182.full AB - Objectives Sleep disorders are a global issue, and supplements for sleep and new devices for daily sleep status assessment are becoming widely available. Gamma-aminobutyric acid (GABA) and L-theanine are commonly used dietary supplements to improve sleep. This study examined whether the combined GABA (700 mg/day) and L-theanine (200 mg/day) intake improve sleep in adults with sleep problems and whether the Fitbit Charge 5 can detect sleep status changes the supplements induced.Methods Participants received the supplements for four weeks, and changes in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) and sleep-related data measured by the Fitbit Charge 5 were evaluated before and after the intake of the supplements.Results Results obtained from 19 participants indicated significant improvement in the total PSQI score (9.42 ± 1.80 to 6.26 ± 1.66 (mean ± standard deviation), p<0.001). Sleep score improvement was insignificant for the Fitbit data(N=17). However, sleep recovery scores improved significantly (p=0.042). In addition, heart rate during sleep decreased with a significant difference of 1.3 bpm decrease in the first week of intake (p = 0.045).Conclusions The simultaneous intake of GABA and L-theanine improved sleep in adults, and the Fitbit Charge 5 could detect improvements in objective information regarding sleep status.Competing Interest StatementThis study was funded by Nestlé Health Science Company, Nestlé Japan Ltd. Yukikazu Kamada is an employee of Nestlé Health Science Company.Clinical TrialUMIN Study ID: UMIN000050613Funding StatementThis study was funded by the Nestlé Health Science Company, Nestlé Japan Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the Declaration of Helsinki and approved by the Institutional Review Board of Brain Care Clinic (BCC230203-2, date of approval: February 3, 2023)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are presented in this manuscript. All the data are available from the authors upon request.